Lannett Company - News Releases https://lannett.investorroom.com/ Lannett is a US-based pharmaceuticals company manufacturing and/or commercially marketing over 100 generic pharmaceutical products. LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 CASES TO SIGNIFICANTLY STRENGTHEN FINANCIAL POSITION https://lannett.investorroom.com/2023-05-02-LANNETT-COMPANY,-INC-FILES-PREPACKAGED-CHAPTER-11-CASES-TO-SIGNIFICANTLY-STRENGTHEN-FINANCIAL-POSITION Tue, 02 May 2023 22:56:00 -0400 https://lannett.investorroom.com/2023-05-02-LANNETT-COMPANY,-INC-FILES-PREPACKAGED-CHAPTER-11-CASES-TO-SIGNIFICANTLY-STRENGTHEN-FINANCIAL-POSITION Lannett Company, Inc. Enters Into Restructuring Support Agreement https://lannett.investorroom.com/2023-05-01-Lannett-Company,-Inc-Enters-Into-Restructuring-Support-Agreement Mon, 01 May 2023 06:55:00 -0400 https://lannett.investorroom.com/2023-05-01-Lannett-Company,-Inc-Enters-Into-Restructuring-Support-Agreement NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS https://lannett.investorroom.com/2023-04-20-NYSE-TO-SUSPEND-TRADING-IMMEDIATELY-IN-LANNETT-COMPANY,-INC-LCI-AND-COMMENCE-DELISTING-PROCEEDINGS Thu, 20 Apr 2023 06:53:00 -0400 https://lannett.investorroom.com/2023-04-20-NYSE-TO-SUSPEND-TRADING-IMMEDIATELY-IN-LANNETT-COMPANY,-INC-LCI-AND-COMMENCE-DELISTING-PROCEEDINGS LANNETT SHARES UPDATE https://lannett.investorroom.com/2023-04-04-LANNETT-SHARES-UPDATE Tue, 04 Apr 2023 06:55:00 -0400 https://lannett.investorroom.com/2023-04-04-LANNETT-SHARES-UPDATE LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE https://lannett.investorroom.com/2023-02-01-LANNETT-REPORTS-IMPROVED-FISCAL-2023-SECOND-QUARTER-FINANCIAL-RESULTS-RAISES-FULL-YEAR-GUIDANCE Wed, 01 Feb 2023 16:15:00 -0500 https://lannett.investorroom.com/2023-02-01-LANNETT-REPORTS-IMPROVED-FISCAL-2023-SECOND-QUARTER-FINANCIAL-RESULTS-RAISES-FULL-YEAR-GUIDANCE LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT https://lannett.investorroom.com/2023-01-25-LANNETT-ANNOUNCES-1-FOR-4-REVERSE-STOCK-SPLIT Wed, 25 Jan 2023 16:30:00 -0500 https://lannett.investorroom.com/2023-01-25-LANNETT-ANNOUNCES-1-FOR-4-REVERSE-STOCK-SPLIT LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1 https://lannett.investorroom.com/2023-01-25-LANNETT-TO-REPORT-FISCAL-2023-SECOND-QUARTER-FINANCIAL-RESULTS,-HOST-CONFERENCE-CALL-ON-WEDNESDAY,-FEBRUARY-1 Wed, 25 Jan 2023 06:52:00 -0500 https://lannett.investorroom.com/2023-01-25-LANNETT-TO-REPORT-FISCAL-2023-SECOND-QUARTER-FINANCIAL-RESULTS,-HOST-CONFERENCE-CALL-ON-WEDNESDAY,-FEBRUARY-1 LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS https://lannett.investorroom.com/2023-01-04-LANNETT-PROVIDES-DEVELOPMENT-UPDATE-ON-BIOSIMILAR-INSULIN-PRODUCTS Wed, 04 Jan 2023 06:52:00 -0500 https://lannett.investorroom.com/2023-01-04-LANNETT-PROVIDES-DEVELOPMENT-UPDATE-ON-BIOSIMILAR-INSULIN-PRODUCTS LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM https://lannett.investorroom.com/2022-11-07-LANNETT-ANNOUNCES-PATENT-LICENSES-FOR-THE-PEN-INJECTOR-DELIVERY-DEVICE-TO-BE-USED-FOR-ITS-INSULIN-GLARGINE-AND-INSULIN-ASPART-DEVELOPMENT-PROGRAM Mon, 07 Nov 2022 06:52:00 -0500 https://lannett.investorroom.com/2022-11-07-LANNETT-ANNOUNCES-PATENT-LICENSES-FOR-THE-PEN-INJECTOR-DELIVERY-DEVICE-TO-BE-USED-FOR-ITS-INSULIN-GLARGINE-AND-INSULIN-ASPART-DEVELOPMENT-PROGRAM LANNETT REPORTS BETTER THAN EXPECTED FINANCIAL RESULTS FOR FISCAL 2023 FIRST-QUARTER; REITERATES FULL-YEAR GUIDANCE https://lannett.investorroom.com/2022-11-02-LANNETT-REPORTS-BETTER-THAN-EXPECTED-FINANCIAL-RESULTS-FOR-FISCAL-2023-FIRST-QUARTER-REITERATES-FULL-YEAR-GUIDANCE Wed, 02 Nov 2022 16:15:00 -0400 https://lannett.investorroom.com/2022-11-02-LANNETT-REPORTS-BETTER-THAN-EXPECTED-FINANCIAL-RESULTS-FOR-FISCAL-2023-FIRST-QUARTER-REITERATES-FULL-YEAR-GUIDANCE